{
    "id": 17320,
    "fullName": "STAT3 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type STAT3 indicates that no mutation has been detected within the STAT3 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6774,
        "geneSymbol": "STAT3",
        "terms": [
            "STAT3",
            "ADMIO",
            "ADMIO1",
            "APRF",
            "HIES"
        ]
    },
    "variant": "wild-type",
    "createDate": "01/28/2016",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4283,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ISIS-STAT3rx (AZD9150) treatment resulted in tumor shrinkage in 50% (3/6) and partial response in 22% (2/6) of diffuse large B-cell lymphoma patients (PMID: 26582900).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4478,
                    "pubMedId": 26582900,
                    "title": "AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582900"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4282,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ISIS-STAT3rx (AZD9150) treatment resulted in stable disease or partial response in 44% (11/25) of patients with lymphoma or advanced solid tumors (PMID: 26582900).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4478,
                    "pubMedId": 26582900,
                    "title": "AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582900"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4349,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed fibroblast cell lines harboring basal Stat3 activity demonstrated reduced sensitivity to SH4-54 treatment-induced growth inhibition in culture (PMID: 26088127).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 3493,
                "therapyName": "SH4-54",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4499,
                    "pubMedId": 26088127,
                    "title": "Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26088127"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4285,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ISIS-STAT3rx (AZD9150) treatment inhibited tumor growth in non-small cell lung cancer xenograft models (PMID: 26582900).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4478,
                    "pubMedId": 26582900,
                    "title": "AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582900"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4342,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed fibroblast cell lines harboring basal Stat3 activity demonstrated reduced sensitivity to SH5-07 treatment-induced growth inhibition in culture (PMID: 26088127).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 3494,
                "therapyName": "SH5-07",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4499,
                    "pubMedId": 26088127,
                    "title": "Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26088127"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4655,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited Stat3 phosphorylation, decreased expression of Stat genes, and reduced growth of human hepatocellular cancer cell lines in culture and in xenografts (PMID: 25883212).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4664,
                    "pubMedId": 25883212,
                    "title": "LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25883212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4284,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ISIS-STAT3rx (AZD9150) treatment resulted in stable disease in 1 of 2 follicular lymphma patients (PMID: 26582900).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4478,
                    "pubMedId": 26582900,
                    "title": "AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582900"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6199,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PG-S3-001 inhibited Stat3 activation and growth of pancreatic cells in culture and in patient derived xenografts (PMID: 26873728).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 4091,
                "therapyName": "PG-S3-001",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5424,
                    "pubMedId": 26873728,
                    "title": "Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26873728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17606,
            "profileName": "STAT3 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}